Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Change in Account Payables (2016 - 2025)

Seres Therapeutics' Change in Account Payables history spans 11 years, with the latest figure at -$515000.0 for Q3 2025.

  • For Q3 2025, Change in Account Payables fell 1455.26% year-over-year to -$515000.0; the TTM value through Sep 2025 reached -$6.6 million, down 71.97%, while the annual FY2024 figure was -$2.9 million, 74.61% up from the prior year.
  • Change in Account Payables for Q3 2025 was -$515000.0 at Seres Therapeutics, down from $79000.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $7.2 million in Q2 2022 and bottomed at -$6.5 million in Q1 2022.
  • The 5-year median for Change in Account Payables is $38000.0 (2024), against an average of -$281842.1.
  • The largest annual shift saw Change in Account Payables soared 908.86% in 2022 before it crashed 1455.26% in 2025.
  • A 5-year view of Change in Account Payables shows it stood at $4.6 million in 2021, then grew by 19.04% to $5.5 million in 2022, then tumbled by 192.41% to -$5.0 million in 2023, then rose by 17.4% to -$4.2 million in 2024, then soared by 87.63% to -$515000.0 in 2025.
  • Per Business Quant, the three most recent readings for MCRB's Change in Account Payables are -$515000.0 (Q3 2025), $79000.0 (Q2 2025), and -$2.0 million (Q1 2025).